FOXC2 Promotes Vasculogenic Mimicry in Ovarian Cancer

FOXC2 is a forkhead family transcription factor that plays a critical role in specifying mesenchymal cell fate during embryogenesis. FOXC2 expression is associated with increased metastasis and poor survival in various solid malignancies. Using in vitro and in vivo assays in mouse ovarian cancer cel...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-10, Vol.14 (19), p.4851
Main Authors: Recouvreux, Maria Sol, Miao, Jiangyong, Gozo, Maricel C, Wu, Jingni, Walts, Ann E, Karlan, Beth Y, Orsulic, Sandra
Format: Article
Language:English
Subjects:
Angiogenesis
Anoikis
Antibodies
Blood vessels
Cancer cells
Cell culture
Cell differentiation
Cell fate
Cell growth
Development and progression
Diabetes
Drug resistance
Embryogenesis
Forkhead protein
Genetic aspects
Health aspects
Hypoxia
Laboratory animals
Medical prognosis
Mesenchyme
Metastases
Metastasis
Mimicry
Nutrients
Ovarian cancer
Stem cells
Tumor cell lines
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:FOXC2 is a forkhead family transcription factor that plays a critical role in specifying mesenchymal cell fate during embryogenesis. FOXC2 expression is associated with increased metastasis and poor survival in various solid malignancies. Using in vitro and in vivo assays in mouse ovarian cancer cell lines, we confirmed the previously reported mechanisms by which FOXC2 could promote cancer growth, metastasis, and drug resistance, including epithelial-mesenchymal transition, stem cell-like differentiation, and resistance to anoikis. In addition, we showed that FOXC2 expression is associated with vasculogenic mimicry in mouse and human ovarian cancers. FOXC2 overexpression increased the ability of human ovarian cancer cells to form vascular-like structures in vitro, while inhibition of FOXC2 had the opposite effect. Thus, we present a novel mechanism by which FOXC2 might contribute to cancer aggressiveness and poor patient survival.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14194851